In vitro and in vivo characterization of a novel liposomal a butorphanol formulation for treatment of pruritus

Acta Dermato-Venereologica

Volumn 88, Issue 4, 2008, Pages 327-330

  Lim, Grace J ^a,b   Ishiuji, Yozo ^a   Dawn, Aerlyn ^a   Harrison, Benjamin ^a   Kim, Do Won ^b   Atala, Anthony ^a   Yosipovitch, Gil ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Butorphanol; Kappa opioid; Liposome; Pruritus; Transdermal delivery

Indexed keywords

BUTORPHANOL TARTRATE; CHOLESTEROL; EGG YOLK PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PLACEBO; POLYOXYETHYLENE; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DIFFUSION CHAMBER; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; ENCAPSULATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PRURITUS; RAT; SKIN EXAMINATION; SKIN INFLAMMATION; SKIN IRRITATION; SKIN PENETRATION; STEADY STATE; SUSTAINED DRUG RELEASE; VISCOSITY;

ANALGESICS, OPIOID; ANIMALS; BUTORPHANOL; FEMALE; HUMANS; LIPOSOMES; PRURITUS; RATS; RATS, SPRAGUE-DAWLEY; SKIN; VISCOSITY;

EID: 47749140066     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0480     Document Type: Article

References (21)

1. Pan ZZ. mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 1998; 19: 94-98.
2. Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, Nagase H. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 2003; 477: 29-35.
3. Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002; 435: 259-264.
4. Yosipovitch G. Pruritus: an update. Current Problems in Dermatology 2003; 15: 137-164.
5. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361:690-694.
6. Bergasa NV. An approach to the management of the pruritus of cholestasis. Clin Liver Dis 2004; 8: 55-66, vi.
7. Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54: 527-531.
8. Touitou E, Junginger HE, Weiner ND, Nagai T, Mezei M. Liposomes as carriers for topical and transdermal delivery. J Pharm Sci 1994; 83: 1189-1203.
9. Calvagno MG, Celia C, Paolino D, Cosco D, Iannone M, Castelli F, et al. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes. Curr Drug Deliv 2007; 4: 89-101.
10. Lim JO, Kim SJ, Pouliot R, Baek WY. Enhanced transdermal delivery of local anesthetics by liposome formulation of local anesthetic mixture. Key Engineering Materials 2005; No. 277/279: 45-50.
11. Li SK, Ghanem AH, Peck KD, Higuchi WI. Characterization of the transport pathways induced during low to moderate voltage iontophoresis in human epidermal membrane. J Pharm Sci 1998; 87: 40-48.
12. Weiss SC, Nguyen J, Chon S, Kimball AB. A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-term treatment of stasis dermatitis. J Drugs Dermatol 2005; 4: 339-345.
13. Understanding rheology. Emerson & Cuming, Inc. 2000. Emerson & Cuming, Inc. 7-29-2007. Available from: http:// www.emersoncuming.com/other// understandingrheology. pdf
14. Bigliardi PL, Stammer H, Jost G, Rufli T, Buchner S, Bigliardi-Qi M. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007; 56: 979-988.
15. Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007; 127: 2228-2235.
16. Wikström B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005; 16: 3742-3747.
17. Lee H, Naughton NN, Woods JH, Ko MC. Effects of butorphanol on morphine-induced itch and analgesia in primates. Anesthesiology 2007; 107: 478-485.
18. Dershwitz M, Rosow CE, DiBiase PM, Zaslavsky A. Comparison of the sedative effects of butorphanol and midazolam. Anesthesiology 1991; 74: 717-724.
19. Greenwald MK, Stitzer ML. Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine. Drug Alcohol Depend 1998; 53: 17-30.
20. United States Patent 6197344: Butorphanol Sustained Release Formulations. Available from: http://www. freepatentsonline.com
21. AHFS Drug Information, Butorphanol, American Society of Hospital Pharmacists, Inc, Bethesda, MD, USA.